Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    9196082 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
Condition: Cat Allergy
Interventions: Drug: Omalizumab;   Drug: Placebo

Indicates status has not been verified in more than two years